EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• EZH2 is the catalytic subunit of Polycomb Repressive Complex 2 (PRC2).
• PRC2 mediates gene silencing through Histone H3 lysine 27 methylation.
• EZH2 has critical roles in lymphoid system development and is implicated in lymphomagenesis.

Purpose of the Study:

• To discuss the physiological and pathogenic roles of EZH2 in the lymphoid context.
• To explore the causes of EZH2 aberrance and its mechanisms in lymphomagenesis.
• To summarize therapeutic strategies targeting EZH2.

Main Methods:

• Literature review and synthesis of current research on EZH2.
• Analysis of EZH2's function in normal lymphoid development and cancer pathogenesis.
• Examination of epigenetic silencing, post-translational modifications, and interactions with the tumor microenvironment and other partners.

Main Results:

• EZH2's dual role in normal lymphoid development and its oncogenic function in B and T cell malignancies.
• Identification of various genetic and non-genetic causes for EZH2 deregulation.
• Elucidation of EZH2's contribution to lymphomagenesis via epigenetic mechanisms, PTMs, and microenvironmental interactions.

Conclusions:

• EZH2 dysregulation is a key driver in lymphoid cancers.
• Targeting EZH2 directly or its upstream signaling pathways offers promising therapeutic avenues.
• Further research into EZH2's complex roles is crucial for developing effective cancer treatments.